Accretion Pharmaceuticals Limited
Bookbuilding IPO · NSE
- Price band
- ₹101 - ₹101
- Lot size
- 1,200 shares
- Issue amount
- ₹29.75 cr
- Total subscription
- 7.32×
- Opens
- 14 May 2025
- Closes
- 16 May 2025
- Allotment
- 19 May 2025
- Listing
- 21 May 2025
Offer at a glance
Issue overview
- Issue size
- 29,46,000 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,21,200
- Fresh issue
- ₹29.75 cr
- Offer for sale
- ₹0 cr
- Registrar
- Kfin Technologies Limited
- Listing exchange
- NSE
- Maximum investment
- ₹1,21,200
- Issue type
- Bookbuilding IPO
- Shares before issue
- 81,70,000
- Shares after issue
- 1,11,16,000
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 1,200 | ₹1,21,200 |
| HNI | 2 | 2,400 | ₹2,42,400 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | — | 4 |
| NIB | — | 889 |
| RETAIL | — | 10,746 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 1.43 | 17.37 |
| RETAIL | 12.35 | 130.24 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Dec-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| EPS | 8.74 | 9.69 | 0.26 |
| ROE | 38.54 | 72.47 | 2.7 |
| ROCE | 30.14 | 36.73 | 9.87 |
| RONW | 38.54 | 72.47 | 2.7 |
| PRE IPO(PE) | 0 | 21.29 | 0 |
| POST IPO(PE) | 16.08 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Accretion Pharmaceuticals Limited, founded in 2012 and based in Ahmedabad-Sanand, Gujarat, is a pharmaceutical company active in formulations and contract manufacturing with 83 employees as of January 2025. The company offers a wide range of products including tablets, capsules, syrups, ointments, creams, medicated shampoos, dusting powders, and ayurvedic wellness products, and also provides third-party manufacturing services. The proposed fund usage mainly focuses on growth capex such as facility upgrades and new machinery to increase capacity and support exports to 20+ countries, along with working capital needs, limited debt repayment, and flexibility for general purposes, helping the company scale operations, maintain quality standards, improve liquidity, and support future expansion opportunities.
Strengths
- Experienced Leadership: Run by promoters and management with strong industry expertise.
- Strong Relationships: Long-standing client & supplier partnerships support business stability.
- Quality Focus: ISO-certified systems ensure high-quality pharmaceutical & healthcare products.
Risk factors
- Ongoing Legal Cases: Current court proceedings could harm the company’s reputation and business performance.
- Changing Regulations: Not keeping up with updated pharmaceutical laws may lead to disruptions and affect business operations.
- Regulatory Checks: Unfavorable inspection results from authorities or clients could lead to penalties or damage the company’s image.
Promoters
Mr. Mayur Popatlal Sojitra
Mr. Harshad Nanubhai Rathod
Mr. Vivek Ashok Kumar Patel
Mr. Hardik Mukundbhai Prajapati.
Registrar & documents
Lead manager
Jawa Capital Services Private Limited
Registrar & contacts
Kfin Technologies Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvad Sanand
+91-97148 82929
[email protected]Company website ↗Understanding ACCPL IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.